Proportion of families with pathogenic mutations for each Manchester score range
| BRCA1 | BRCA1 * | BRCA2 | BRCA2† | |
|---|---|---|---|---|
| *Excluding male breast cancer families with BRCA2 mutations (n = 15); †excluding ovarian cancer families with BRCA1 mutations (n = 79). | ||||
| 30+ | 15/19 (79%) | 15/18 (83%) | 3/9 (33%) | 3/3 (100%) |
| 25–29 | 7/14 (50%) | 7/12 (58%) | 5/11 (45%) | 5/6 (83%) |
| 20–24 | 19/45 (42%) | 19/42 (45%) | 8/28 (30%) | 8/14 (57%) |
| 15–19 | 28/80 (35%) | 28/75 (37%) | 21/74 (28%) | 21/57 (37%) |
| 12–14 | 19/120 (16%) | 19/118 (16%) | 20/120 (17%) | 20/103 (20%) |
| 10–11 | 12/119 (10%) | 12/117 (10%) | 21/140 (15%) | 21/125 (17%) |
| 8–9 | 4/163 (2.5%) | 4/163 (2.5%) | 14/180 (8%) | 14/175 (8%) |
| <8 | 3/360 (0.9%) | 3/360 (0.9%) | 7/359 (2%) | 7/359 (2%) |
| Total | 107/921 (11.5%) | 107/906 (11.8%) | 99/921 (10.5%) | 99/842 (11.7%) |